SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Hikal reports Profit after tax of Rs 509.20 Mln, in the March 2021 quarter

06 May 2021 Evaluate
A decent increase of about 40.49% in the sales to Rs. 5324.60 millions was observed for the quarter ended March 2021. The sales figure stood at Rs. 3789.90 millions during the year-ago period.The company almost doubled its revenue to Rs. 509.20 millions  from Rs. 244.70 millions in the quarter ended March 2021.Operating profit surged to 1121.30 millions from the corresponding previous quarter of 723.60 millions.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202103 202003 % Var 202103 202003 % Var 202003 201903 % Var
Sales 5324.60 3789.90 40.49 17204.40 15072.60 14.14 15072.60 15896.10 -5.18
Other Income 28.70 17.30 65.90 49.80 37.00 34.59 37.00 22.60 63.72
PBIDT 1121.30 723.60 54.96 3278.10 2768.50 18.41 2768.50 3003.90 -7.84
Interest 99.70 137.00 -27.23 361.40 524.20 -31.06 524.20 584.30 -10.29
PBDT 1021.60 586.60 74.16 2916.70 2090.30 39.53 2090.30 2419.60 -13.61
Depreciation 215.50 209.40 2.91 852.40 824.60 3.37 824.60 928.80 -11.22
PBT 806.10 377.20 113.71 2064.30 1265.70 63.10 1265.70 1490.80 -15.10
TAX 296.90 132.50 124.08 732.80 421.40 73.90 421.40 460.10 -8.41
Deferred Tax -45.80 44.50 -202.92 -62.70 74.40 -184.27 74.40 5.10 1358.82
PAT 509.20 244.70 108.09 1331.50 844.30 57.70 844.30 1030.70 -18.08
Equity 246.60 246.60 0.00 246.60 246.60 0.00 246.60 246.60 0.00
PBIDTM(%) 21.06 19.09 10.30 19.05 18.37 3.73 18.37 18.90 -2.80

Hikal Share Price

192.15 3.60 (1.91%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×